Top

Published in:

01-03-2017 | Original Communication

High-sensitivity cardiac troponin I and NT-proBNP as predictors of incident dementia and Alzheimer’s disease: the FINRISK Study

Authors: Juho Tynkkynen, Jussi A. Hernesniemi, Tiina Laatikainen, Aki S. Havulinna, Perttu Salo, Stefan Blankenberg, Tanja Zeller, Veikko Salomaa

Published in: Journal of Neurology | Issue 3/2017

Abstract

Cardiac troponin and N-terminal pro-brain natriuretic peptide (NT-proBNP) are known to associate with incident dementia. The purpose of our study was to examine whether high-sensitivity cardiac troponin I (hs-TnI) and NT-proBNP are associated with incident dementia and Alzheimer’s disease (AD) independently of each other. Our study was a part of the national population-based health examination survey, FINRISK 1997, with a total sample of 7114 subjects, including 407 incident dementia cases and 319 AD cases during the follow-up time of 18 years. Using multivariate Cox regression analyses, we calculated the hazard ratios (HR) for hs-TnI and NT-proBNP. Analyses were adjusted for the previously known dementia/AD risk factors, including the apoE genotype. NT-proBNP was independently associated with incident dementia (HR 1.32, 95% CI 1.17–1.49) and AD (HR 1.30, 95% CI 1.13–1.5). Hs-TnI was also associated with incident dementia (HR 1.12, 95% CI 1.02–1.23), but not independent of NT-proBNP (HR 1.10, 95% CI 0.99–1.21). Hs-TnI was not associated with incident AD. The results remained similar in cause-specific Cox regression models and among subjects over 40 years of age. NT-proBNP and hs-TnI improved the reclassification of dementia risk in 10 years follow-up, and hs-TNI also in 18 years of follow-up. Neither hs-TnI nor NT-proBNP was able to outperform each other in risk reclassification of dementia. Both cardiovascular biomarkers, NT-proBNP and hs-TnI, were associated with incident dementia independently of traditional dementia risk factors including the apoE genotype. NT-proBNP was also associated with AD. Both markers offered a better dementia risk reclassification compared with traditional risk factors.

Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, Skoog I (2005) High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64:1689–1695CrossRefPubMed

Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 322:1447–1451CrossRefPubMedPubMedCentral

Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M (2007) Serum cholesterol changes after midlife and late-life cognition: 21-year follow-up study. Neurology 68:751–756CrossRefPubMed

Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breitner JC, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB (2005) Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 65:1045–1050CrossRefPubMed

Kaffashian S, Dugravot A, Elbaz A, Shipley MJ, Sabia S, Kivimaki M, Singh-Manoux A (2013) Predicting cognitive decline: A dementia risk score vs the Framingham vascular risk scores. Neurology 80:1300–1306CrossRefPubMedPubMedCentral

Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J (2006) Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 5:735–741CrossRefPubMed

Exalto LG, Quesenberry CP, Barnes D, Kivipelto M, Biessels GJ, Whitmer RA (2013) Midlife risk score for the prediction of dementia four decades later. Alzheimers Dement

Reitz C, Brickman AM, Luchsinger JA, Wu WE, Small SA, Tang MX (2007) Frequency of subclinical heart disease in elderly persons with dementia. Am J Geriatr Cardiol 16:183–188CrossRefPubMedPubMedCentral

Ganguli M, Fu B, Snitz BE, Hughes TF, Chang CC (2013) Mild cognitive impairment: incidence and vascular risk factors in a population-based cohort. Neurology 80:2112–2120CrossRefPubMedPubMedCentral

10.

Folsom AR, Nambi V, Bell EJ, Oluleye OW, Gottesman RF, Lutsey PL, Huxley RR, Ballantyne CM (2013) Troponin T, N-terminal pro-B-type natriuretic Peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke 44:961–967CrossRefPubMedPubMedCentral

11.

Nambi V, Liu X, Chambless LE, de Lemos JA, Virani SS, Agarwal S, Boerwinkle E, Hoogeveen RC, Aguilar D, Astor BC, Srinivas PR, Deswal A, Mosley TH, Coresh J, Folsom AR, Heiss G, Ballantyne CM (2013) Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk–the atherosclerosis risk in communities study. Clin Chem 59:1802–1810CrossRefPubMedPubMedCentral

12.

Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, Kuulasmaa K, Yarnell J, Schnabel RB, Wild PS, Munzel TF, Lackner KJ, Tiret L, Evans A, Salomaa V, MORGAM Project (2010) Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121:2388–2397CrossRef

13.

Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, Lindahl B, Giannitsis E, Hasin Y, Galvani M, Tubaro M, Alpert JS, Biasucci LM, Koenig W, Mueller C, Huber K, Hamm C, Jaffe AS, Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care (2010) Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 31:2197–2204CrossRef

14.

Schneider AL, Rawlings AM, Sharrett AR, Alonso A, Mosley TH, Hoogeveen RC, Ballantyne CM, Gottesman RF, Selvin E (2014) High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. Eur Heart J 35:1817–1824CrossRefPubMedPubMedCentral

15.

Kerola T, Nieminen T, Hartikainen S, Sulkava R, Vuolteenaho O, Kettunen R (2010) B-type natriuretic peptide as a predictor of declining cognitive function and dementia–a cohort study of an elderly general population with a 5-year follow-up. Ann Med 42:207–215CrossRefPubMed

16.

Feinkohl I, Keller M, Robertson CM, Morling JR, Williamson RM, Nee LD, McLachlan S, Sattar N, Welsh P, Reynolds RM, Russ TC, Deary IJ, Strachan MW, Price JF, Edinburgh Type 2 Diabetes Study (ET2DS) Investigators (2013) Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 36:2779–2786CrossRef

17.

Tynkkynen J, Laatikainen T, Salomaa V, Havulinna AS, Blankenberg S, Zeller T, Hernesniemi JA (2015) NT-proBNP and the risk of dementia: a prospective cohort study with 14 years of follow-up. J Alzheimers Dis 44:1007–1013PubMed

18.

Mirza SS, de Bruijn RF, Koudstaal PJ, van den Meiracker AH, Franco OH, Hofman A, Tiemeier H, Ikram MA (2015) The N-terminal pro B-type natriuretic peptide, and risk of dementia and cognitive decline: a 10-year follow-up study in the general population. J Neurol Neurosurg Psychiatry

19.

Daniels LB, Clopton P, deFilippi CR, Sanchez OA, Bahrami H, Lima JA, Tracy RP, Siscovick D, Bertoni AG, Greenland P, Cushman M, Maisel AS, Criqui MH (2015) Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 170:1170–1183CrossRefPubMedPubMedCentral

20.

The World Health Organization (1988) MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 41:105–114

21.

Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Mannisto S, Sundvall J, Jousilahti P, Salomaa V, Valsta L, Puska P (2010) Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 39:504–518CrossRefPubMed

22.

Pajak A, Kuulasmaa K, Tuomilehto J, Ruokokoski E (1988) Geographical variation in the major risk factors of coronary heart disease in men and women aged 35–64 years. The WHO MONICA Project. World Health Stat Q 41:115–140

23.

Sundvall J, Leiviska J, Alfthan G, Vartiainen E (2007) Serum cholesterol during 27 years: assessment of systematic error and affecting factors and their role in interpreting population trends. Clin Chim Acta 378:93–98CrossRefPubMed

24.

Leiviska J, Sundvall J, Alfthan G, Tahtela R, Salomaa V, Jauhiainen M, Vartiainen E (2013) What have we learnt about high-density lipoprotein cholesterol measurements during 32 years? Experiences in Finland 1980-2012. Clin Chim Acta 415:118–123CrossRefPubMed

25.

Neumann JT, Havulinna AS, Zeller T, Appelbaum S, Kunnas T, Nikkari S, Jousilahti P, Blankenberg S, Sydow K, Salomaa V (2014) Comparison of three troponins as predictors of future cardiovascular events–prospective results from the FINRISK and BiomaCaRE studies. PLoS ONE 9:e90063CrossRefPubMedPubMedCentral

26.

Tynkkynen J, Hernesniemi JA, Laatikainen T, Havulinna AS, Sundvall J, Leiviska J, Salo P, Salomaa V (2016) Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer’s disease: the National Finnish population study (FINRISK). Age (Dordr)

27.

Working group appointed by the Finnish Medical Society Duodecim, Societas Gerontologica Fennica, the Finnish Neurological Society, Finnish Psychogeriatric Association and the Finnish Association for General Practice. (2010) Dementia (online). Current Care guideline. Helsinki: Finnish Medical Society Duodecim (referred 21 November 2013). Dissertation or Thesis

28.

Solomon A, Ngandu T, Soininen H, Hallikainen MM, Kivipelto M, Laatikainen T (2013) Validity of dementia and Alzheimer disease diagnoses in Finnish national registers. Alzheimers Dement

29.

Sv Buuren, Groothuis-Oudshoorn K (2011) mice: Multivariate Imputation by Chained Equations in R. J Stat Softw 45:1–67

30.

Team RC (2013) R: A language and environment for statistical computing

31.

Therneau TM (2014) A package for survival analysis in S

32.

Schwarzer G (2015) meta: general package for meta-analysis

33.

Gerds TA, Scheike TH (2015) riskRegression: risk regression models for survival analysis with competing risks

34.

Wickham H (2009) ggplot2: elegant graphics for data analysis. Springer-Verlag, New YorkCrossRef

35.

Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, Hasin Y, Biasucci LM, Giannitsis E, Lindahl B, Koenig W, Tubaro M, Collinson P, Katus H, Galvani M, Venge P, Alpert JS, Hamm C, Jaffe AS, Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care (2012) Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 33:2001–2006CrossRef

36.

Rauchenzauner M, Haberlandt E, Rosslhuber C, Luef G, Otto M, Hammerer-Lercher A, Griesmacher A, Rostasy K (2009) Cerebrospinal fluid and serum NT-proBNP concentrations in children with epilepsy. Epilepsy Res 86:131–137CrossRefPubMed

37.

Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis. PLoS One 6:e18850CrossRefPubMedPubMedCentral

38.

Kirchhoff C, Stegmaier J, Bogner V, Buhmann S, Mussack T, Kreimeier U, Mutschler W, Biberthaler P (2006) Intrathecal and systemic concentration of NT-proBNP in patients with severe traumatic brain injury. J Neurotrauma 23:943–949CrossRefPubMed

39.

Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Raiha P, Karja-Koskenkari P, Mahonen M, Niemela M, Kuulasmaa K, Palomaki P, Mustonen J, Lehtonen A, Arstila M, Vuorenmaa T, Lehto S, Miettinen H, Torppa J, Tuomilehto J, Kesaniemi YA, Pyorala K, Salomaa V (2005) The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 12:132–137PubMed

Title: High-sensitivity cardiac troponin I and NT-proBNP as predictors of incident dementia and Alzheimer’s disease: the FINRISK Study
Authors: Juho Tynkkynen
Jussi A. Hernesniemi
Tiina Laatikainen
Aki S. Havulinna
Perttu Salo
Stefan Blankenberg
Tanja Zeller
Veikko Salomaa
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 3/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-016-8378-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

High-sensitivity cardiac troponin I and NT-proBNP as predictors of incident dementia and Alzheimer’s disease: the FINRISK Study

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Edwin Bickerstaff (1920–2008)

Global and regional annual brain volume loss rates in physiological aging

Dystonia: opportunities to gain insights into underlying pathophysiological mechanisms

MDS clinical diagnostic criteria for Parkinson’s disease in China

Reduced serum myostatin concentrations associated with genetic muscle disease progression

Changes in the severity and subtype of Guillain-Barré syndrome admitted to a specialist Neuromedical ICU over a 25 year period